在口服双胞胎菌补充剂ICC患者免疫治疗后预测益处的诺莫图:一项回顾性研究
Sihui Zhu1,2, Yuncheng Jin1, Juan Zhang1
1Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, 210008, Jiangsu Province, China.
这项研究开发了名图来预测接受免疫治疗的肝脏内胆管癌 (ICC) 患者的结果. 益生菌作为一种新的预后标志物出现,有助于治疗选择和决策.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 预测生物标志物 预测生物标志物
背景情况:
- 肝脏内胆管癌 (ICC) 是一种具有挑战性的恶性瘤.
- 针对ICC免疫治疗反应的预测模型对于个性化治疗至关重要.
研究的目的:
- 开发和验证用于预测接受免疫治疗的ICC患者的整体存活率 (OS) 和无进展存活率 (PFS) 的诺姆图.
- 在ICC中确定免疫治疗反应的新预后因素.
主要方法:
- 对75名接受免疫治疗的ICC患者的回顾性分析.
- 使用一致性指数,校准曲线和决策曲线分析开发和验证名ograms.
- 使用ROC曲线和卡普兰-梅尔分析对预测性能的评估.
主要成果:
- 诺米图表显示了OS (C指数=0.722) 和PFS (C指数=0.678) 的良好预测性能.
- 对OS的独立预后因素包括CA19-9,PVTT等级,双菌和手术.
- 对于PFS的独立预后因素包括CA19-9,白蛋白和胆红素.
- 益生菌 (双菌) 被确定为免疫疗法反应的新型预后标志物.
结论:
- 开发的诺姆图有效预测接受免疫治疗的ICC患者的预后.
- 益生菌代表了ICC免疫治疗中的潜在的新预后标志物.
- 纳米图可以帮助患者选择和免疫治疗的临床决策.
更多相关视频
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
11:40A Co-culture Method to Investigate the Crosstalk Between X-ray Irradiated Caco-2 Cells and PBMC
Published on: January 30, 2018
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
